Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II

Young Joon Hong, Myung Ho Jeong, Jang Ho Bae, Seok Kyu Oh, Seung-Woon Rha, Seung Ho Hur, Sung Yun Lee, Sang Wook Kim, Kwang Soo Cha, In Ho Chae, Tae Hoon Ahn, Kee Sik Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

Original languageEnglish
Pages (from-to)656-667
Number of pages12
JournalKorean Journal of Internal Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Myocardial Infarction
Safety
Glucose
LDL Cholesterol
Unstable Angina
Glycosylated Hemoglobin A
pitavastatin
Fasting
Hospitalization
Heart Failure

Keywords

  • Atherosclerosis
  • Hydroxymethylglu-taryl-CoA reductase inhibitors
  • Lipids
  • Myocardial infarction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Efficacy and safety of pitavastatins in patients with acute myocardial infarction : Livalo in Acute Myocardial Infarction Study (LAMIS) II. / Hong, Young Joon; Jeong, Myung Ho; Bae, Jang Ho; Oh, Seok Kyu; Rha, Seung-Woon; Hur, Seung Ho; Lee, Sung Yun; Kim, Sang Wook; Cha, Kwang Soo; Chae, In Ho; Ahn, Tae Hoon; Kim, Kee Sik.

In: Korean Journal of Internal Medicine, Vol. 32, No. 4, 01.07.2017, p. 656-667.

Research output: Contribution to journalArticle

Hong, Young Joon ; Jeong, Myung Ho ; Bae, Jang Ho ; Oh, Seok Kyu ; Rha, Seung-Woon ; Hur, Seung Ho ; Lee, Sung Yun ; Kim, Sang Wook ; Cha, Kwang Soo ; Chae, In Ho ; Ahn, Tae Hoon ; Kim, Kee Sik. / Efficacy and safety of pitavastatins in patients with acute myocardial infarction : Livalo in Acute Myocardial Infarction Study (LAMIS) II. In: Korean Journal of Internal Medicine. 2017 ; Vol. 32, No. 4. pp. 656-667.
@article{522b805af36342ccb6bbeb840afd18ed,
title = "Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II",
abstract = "Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07{\%} vs. 9.13{\%}, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13{\%} ± 1.21{\%} in 4 mg group and –0.04{\%} ± 1.10{\%} in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.",
keywords = "Atherosclerosis, Hydroxymethylglu-taryl-CoA reductase inhibitors, Lipids, Myocardial infarction",
author = "Hong, {Young Joon} and Jeong, {Myung Ho} and Bae, {Jang Ho} and Oh, {Seok Kyu} and Seung-Woon Rha and Hur, {Seung Ho} and Lee, {Sung Yun} and Kim, {Sang Wook} and Cha, {Kwang Soo} and Chae, {In Ho} and Ahn, {Tae Hoon} and Kim, {Kee Sik}",
year = "2017",
month = "7",
day = "1",
doi = "10.3904/kjim.2016.016",
language = "English",
volume = "32",
pages = "656--667",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of pitavastatins in patients with acute myocardial infarction

T2 - Livalo in Acute Myocardial Infarction Study (LAMIS) II

AU - Hong, Young Joon

AU - Jeong, Myung Ho

AU - Bae, Jang Ho

AU - Oh, Seok Kyu

AU - Rha, Seung-Woon

AU - Hur, Seung Ho

AU - Lee, Sung Yun

AU - Kim, Sang Wook

AU - Cha, Kwang Soo

AU - Chae, In Ho

AU - Ahn, Tae Hoon

AU - Kim, Kee Sik

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

AB - Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

KW - Atherosclerosis

KW - Hydroxymethylglu-taryl-CoA reductase inhibitors

KW - Lipids

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=85025157051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025157051&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.016

DO - 10.3904/kjim.2016.016

M3 - Article

C2 - 28618772

AN - SCOPUS:85025157051

VL - 32

SP - 656

EP - 667

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -